Clinical Trial Update: A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating YH003 in combination with Pebolizumab and albumin paclitaxel for unresectable/metastatic mucosal melanoma has completed its Phase 2 s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma

Drugs mentioned

• Albumin Paclitaxel Injection (nab-paclitaxel)
• Pebolizumab
• YH003 (YH003)

Snippet

Sponsor: Eucure (Beijing) Biopharma Co., Ltd | Conditions: Mucosal Melanoma | Phase 2 | Status: COMPLETED